APPENDIX I SECTION 1 NATURE OF THE VIPER-BP STUDY INTERVENTION
The electronic Baker IDI CV Risk Assessment Tool that originally provided evidence-based advice to reach risk reduction targets for health clinicians was specifically adapted for the VIPER-BP Study.
13 This computer program's primary purpose was to provide GPs with succinct advice and guidance on the available management strategies within the VIPER-BP protocol (including non-pharmacological and pharmacological) to reduce a study participant's individual's cardiovascular risk.
5 An indicative gain (i.e. a reduced absolute risk of a future cardiovascular event) if individual BP 6 and other risk targets were met with easy-tounderstand reports was also directly generated from the program. From a specific VIPER-BP management perspective, the program was designed to prompt the GP to up-titrate valsartanbased therapy according to the randomised intervention arm and their individualised BP target.
6 The program also provided further guidance (based on the national guidelines for the management of hypertension) on the management of patients who had not reached their individualised BP targets on the maximal dose of the relevant valsartan-based titrated treatment regimen. As such, beyond initial clinical profiling (screen shots from Visit 1 and 2) this application was specific to the VIPER-BP intervention arm and its structured program of intensive and forced up-titration of valsartan-based anti-hypertensive therapy (with electronic record keeping and dedicated disks to be used only for those randomised to the VIPER-BP intervention arm). It had a number of core components that enhanced the following aims relative to usual primary care:
• Meeting specific/individual BP targets (the individualised primary end-point)
6
• Other risk reduction/disease management strategies to meet other key cardiovascular risk targets • An overall, reduction in absolute risk of a CV event based on the latest Australian Absolute Cardiovascular Risk Assessment Guidelines
5
The following screen shots tally with each stage of the VIPER-BP Study (Visits 1 to 9). 
